KRAS, one gene present in some cancers, was considered “undruggable” for years.[1] Mutated KRAS is an important target for patients with non-small cell lung cancer (NSCLC) because it’s present in 20-25% of cases.[2] Finally, one drug, sotorasib (Lumakras), is approved to treat one mutant form of KRAS gene, KRAS G12C.[3] This mutation appears in...
Read MoreBiomarkers, Combination Therapy, and Lung Cancer
